文献速递肝病

ALT与qHBsAg比值可预测中国慢性乙型肝炎患者停用恩替卡韦后的长期HBsAg清除

ALT to qHBsAg ratio predicts long-term HBsAg seroclearance after entecavir cessation in Chinese patients with chronic hepatitis B.
PubMed 文献 · J Hepatol · 2024-03-26

本研究随访194例停用恩替卡韦的中国慢性乙型肝炎患者,中位随访70.7个月后28例(14.4%)发生HBsAg清除。从治疗结束至第48周各时间点的ALT/qHBsAg比值均独立预测HBsAg清除,曲线下面积0.799-0.933,阴性预测值>90%,且不受是否重启恩替卡韦影响。

要点

  • 停用恩替卡韦后,ALT/qHBsAg比值独立预测HBsAg清除,风险比范围1.003-1.028。
  • 各时间点ALT/qHBsAg比值诊断性能优良,曲线下面积0.799-0.933,阴性预测值>90%。
  • ALT/qHBsAg比值的预测作用不受患者是否重启恩替卡韦治疗影响。

核心结论

  • 停用恩替卡韦后ALT/qHBsAg比值可预测HBsAg清除,即使患者已重启治疗。
  • 该比值或可降低仅观察而不重启治疗的患者发生严重肝炎发作的风险。

研究设计与样本

  • 本研究随访来自两项既往恩替卡韦停药研究的中国慢性乙型肝炎患者。
  • 所有患者为非肝硬化、HBeAg阴性,治疗结束时HBV DNA检测不到(<20 IU/ml)。
  • 初始48周内密切监测HBV DNA、qHBsAg和ALT,HBV DNA>2,000 IU/ml时重启恩替卡韦而不论ALT水平。
  • 48周后不论是否重启恩替卡韦,每6个月评估一次以监测HBsAg清除。
  • 共纳入194例患者,男性63.4%,平均年龄49.9岁,恩替卡韦治疗中位47.2个月。

主要发现

  • 94例(48.5%)患者治疗结束时qHBsAg<100 IU/ml,158例(81.4%)<1,000 IU/ml。
  • 151例(77.8%)患者最终重启恩替卡韦治疗。
  • 中位随访70.7(51.0-118.2)个月后,28例(14.4%)患者发生HBsAg清除。
  • 治疗结束后第36周和第48周qHBsAg水平独立预测HBsAg清除(均p<0.01),而治疗结束至第24周qHBsAg仅趋势 towards 统计学显著性。
  • 从治疗结束至第48周各时间点ALT/qHBsAg比值均独立预测HBsAg清除(风险比范围1.003-1.028,均p<0.01),曲线下面积0.799-0.933,各时间点阴性预测值>90%,且不受是否重启恩替卡韦影响。

临床怎么用

  • 作者认为ALT/qHBsAg比值或可用于有限疗程核苷(酸)类似物治疗中的患者选择和再治疗决策。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Factors predicting HBsAg seroclearance after treatment cessation, irrespective of nucleos(t)ide analogue (NA) resumption, have important clinical implications. We evaluated predictors of long-term HBsAg seroclearance after entecavir cessation. METHODS: This study followed-up Chinese patients with chronic hepatitis B from two previous studies of entecavir cessation. All patients were non-cirrhotic, HBeAg-negative, with undetectable HBV DNA (<20 IU/ml) at end-of-treatment (EOT). They were monitored closely for 48 weeks with regular HBV DNA, quantitative HBsAg (qHBsAg) and alanine aminotransferase (ALT) measurements. Entecavir was resumed at HBV DNA >2,000 IU/ml, irrespective of ALT levels. After the initial 48 weeks, patients were assessed every 6 months, regardless of entecavir resumption, to monitor for HBsAg seroclearance. RESULTS: A total of 194 patients (63.4% male, mean age 49.9 years, on entecavir for a median of 47.2 months) were recruited; 94 (48.5%) and 158 (81.4%) patients had EOT qHBsAg <100 IU/ml and <1,000 IU/ml, respectively; 151 (77.8%) patients were eventually resumed on entecavir. After follow-up for a median of 70.7 (51.0-118.2) months, 28 (14.4%) patients had HBsAg seroclearance. qHBsAg levels at weeks 36 and 48 after EOT independently predicted HBsAg seroclearance (both p <0.01), whereas qHBsAg from EOT to week 24 only trended towards statistical significance. The ratio of ALT/qHBsAg at all time points from EOT to week 48 independently predicted HBsAg seroclearance (hazard ratios ranging from 1.003-1.028, all p <0.01) with excellent diagnostic performance (area under the receiver-operating characteristic curve 0.799-0.933, negative predictive value >90% at different time points), regardless of whether entecavir was resumed. CONCLUSIONS: The ALT/qHBsAg ratio after entecavir cessation predicts HBsAg seroclearance, even in patients who were resumed on treatment. Its use may mitigate the risk of severe hepatitis flares in patients managed by observation without treatment resumption. IMPACT AND IMPLICATIONS: Current predictors of HBsAg seroclearance after finite nucleos(t)ide analogue (NA) therapy have suboptimal predictive value. We demonstrated that the ALT/qHBsAg ratio may be able to reflect the balance between host control and virological activity. The ALT/qHBsAg ratio at different time points from end-of-treatment till week 48 independently and accurately predicted HBsAg seroclearance in patients who have stopped entecavir. The ALT/qHBsAg ratio may be utilized by clinicians for patient selection and retreatment decisions in finite NA therapy.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Leung RH, Hui RW, Mak LY, et al. ALT to qHBsAg ratio predicts long-term HBsAg seroclearance after entecavir cessation in Chinese patients with chronic hepatitis B. J Hepatol. 2024. PMID: 38527527. doi:10.1016/j.jhep.2024.03.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。